Cost-effectiveness of therapy with a selective aldosterone antagonist eplerenone in patients with heart failure
https://doi.org/10.18705/1607-419X-2012-18-2-108-117
Abstract
Objective. To assess cost-effectiveness of selective aldosterone antagonist eplerenone in patients with chronic heart failure (CHF), including those with prior myocardial infarction. Design and methods. Markov modeling was performed on the basis of the results of multicenter clinical trials EMPHASIS and EPHESUS. Cost analysis was performed on the basis of obligatory medical insurance foundation tariffs in St Petersburg in 2011 year. Results. Eplerenone therapy preserved 17 lives per 1000 patients during 6 months in patients with CHF after myocardial infarction (EF ≤ 40 %) and 24 lives in patients with EF ≤ 30 %. The additional cost per patient is only 15,100-15,200 rubles for 6 months. For patients aged 70 years with CHF FC II, receiving eplerenone therapy, the ratio of cost/effectiveness is 360,800 rubles for one additional year lived. Conclusions. Eplerenone therapy is economically feasible in patients with prior myocardial infarction and left ventricular systolic dysfunction. Maximum effectiveness of eplerenone was found in an early phase of myocardial infarction and in patients with ejection fraction ≤ 30 %. These data prove that the inclusion of eplerenone in the list of the medications used in the state system of drug supply, as well as standards of the medical care is possible and highly required.
About the Authors
A. V. Rudakova
St Petersburg State Chemical-Pharmaceutical Academy
Russian Federation
Russian Federation
O. M. Moiseeva
Russia Almazov Federal Heart, Blood and Endocrinology Centre
Russian Federation
Russian Federation
References
1. Ho K.K., Pinsky J.L., Kannel W.B. et al. The epidemiology of heart failure: the Framingham Study // J. Am. Coll. Cardiol. — 1993. — Vol. 22, № 4, Suppl. A. — Р 6A-13A.
2. Ho K.K., Anderson K.M., Kannel W.B. et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects // Circulation. — 1993. — Vol. 88, № 1. — Р. 107-115.
3. Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т. и др. Современный образ пациента с ХСН в европейской части Российской Федерации (госпитальный этап) // Сердечная недостаточность. — 2011. — Т. 12, № 5. — C. 255-259.
4. Lloyd-Jones D., Adams R.J., Brown T.M. et al. Heart disease and stroke statistics — 2010 update: a report from the American Heart Association // Circulation. — 2010. Vol. 121, № 7. — Р e46-e215.
5. Yousef Z.R., Redwood S.R., Marber M.S. Postinfarction left ventricular remodelling: where are the theories and trials leading us? // Heart. — 2000. — Vol. 83, № 1. — Р 76-80.
6. Bolognese L., Neskovic A., Parodi G. et al. Left ventricular remodeling after primary coronary angioplasty patterns of left ventricular dilation and long-term prognostic implications // Circulation. — 2002. — Vol. 106, № 18. — Р 2351-2357.
7. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group // Circulation. — 1998. — Vol. 97, № 22. — Р 2202-2212.
8. Latini R., Tognoni G., Maggioni A.P. et al. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collaborative Group // J. Am. Coll. Cardiol. — 2000. — Vol. 35, № 7. — Р 1801-1807.
9. Rodriges E.J., Eisenberg M.J., Pilote J. Effects of early and late administration of angiotensin-converting enzyme inhibitors on mortality after myocardial infarction // Am. J. Med. — 2003. — Vol. 115, № 6. — Р 473-479.
10. Exner D.V., Dries D.L., Waclawiw M.A. et al. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the studies of left ventricular dysfunction // J. Am. Coll. Cardiol. — 1999. — Vol. 33, № 4. — Р 916-923.
11. Vantrimpont P., Rouleau J.L., Wun C.C. et al. SAVE Investigators Additive beneficial effects of beta-blockers to angiotensinconverting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study // J. Am. Coll. Cardiol. — 1997. — Vol. 29, № 2. — Р. 229-236.
12. Baker W.L., Coleman C.I., Kluger J. et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease // Ann. Intern. Med. — 2009. — Vol. 151, № 12. — Р 861-871.
13. McKelvie R.S., Yusuf S., Pericak D. et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators // Circulation. — 1999. — Vol. 100, № 10. — Р 1056-1064.
14. The RESOLVD Investigators. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot study // Circulation. — 2000. — Vol. 101, № 4. — Р 378-384.
15. Pitt B., Zannad F., Remme W.J. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure // N. Engl. J. Med. — 1999. — Vol. 341, № 10. — Р. 709-717.
16. Juurlink D.N., Mamdani M.M., Lee D.S. et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study // N. Engl. J. Med. — 2004. — Vol. 351, № 6. — Р. 543-551.
17. Pitt B., Remme W., Zannad F. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction // N. Engl. J. Med. — 2003. — Vol. 348, № 14. — Р 1309-1321.
18. Gheorghiade M., Khan S., Blair J. et al. The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction // Am. Heart J. — 2009. — Vol. 158, № 3. — Р 437-443.
19. Pitt B., White Н., Nicolau J. et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure // J. Am. Coll. Cardiol. — 2005. — Vol. 46, № 3. — Р 425-431.
20. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) // Eur. Heart J. — 2008. — Vol. 29, № 19. — Р 2388-2442.
21. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр) // Сердечная недостаточность. — 2010. — Т. 11, № 1 (57). — С. 69-160.
22. Zannad F., McMurray J.J.V., Krum H. et al. EMPHASISHF Study Group Eplerenone in patients with systolic heart failure and mild symptoms // N. Engl. J. Med. — 2011. — Vol. 364, № 1. — Р 11-21.
23. McKenna C., Burch J., Suekarran S. et al. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure // Health Technol. Assess. — 2010. — Vol. 14, № 24. — Р 1-162.
24. De Pouvourville G., Solesseb A., Beillat M. Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: The EPHESUS study // Arch. Cardiovasc. Dis. — 2008. — Vol. 101, № 9. — Р 515-521.
25. Weintraub W., Zhang Z., Mahoney E. et al. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure // Circulation. — 2005. — Vol. 111, № 9. — Р 1106-1113.
26. Croom K., Plosker G. Eplerenone: a pharmacoeconomic review of its use in patients with post-myocardial infarction heart failure // Pharmacoeconomics. — 2005. — Vol. 23, № 10. — Р 1057-1072.
27. Szucs T., Holm M., Schwenkglenks M. et al. Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction — an analysis of the EPHESUS study from a Swiss perspective // Cardiovasc. Drugs Ther. — 2006. — Vol. 20, № 3. — Р 193-204.
Review
For citations:
Rudakova A.V., Moiseeva O.M. Cost-effectiveness of therapy with a selective aldosterone antagonist eplerenone in patients with heart failure. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2012;18(2):108-117. (In Russ.) https://doi.org/10.18705/1607-419X-2012-18-2-108-117
Views:
1049
Email this article 